Bio-Path Holdings Appoints Ernst & Young as New Auditor
March 11, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Full Year 2019 Financial Results
March 06, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, March 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020
February 28, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
January 08, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
November 26, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
November 25, 2019 14:11 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market
November 21, 2019 11:30 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002
November 21, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2019 Financial Results
November 15, 2019 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019
November 08, 2019 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...